FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313609299> ?p ?o ?g. }

• W4313609299 abstract "Abstract Background: Tocilizumab is considered a critical treatment for severe COVID-19. Thus far, there are no established means of predicting outcomes of administering tocilizumab. Our goal was to determine the factors that predict the prognosis of patients with COVID-19 receiving tocilizumab. Methods: All patients admitted to our hospital from March 2020 to July 2021 who had received tocilizumab for COVID-19 were retrospectively identified from hospital charts. We identified 92 patients who were eligible for this observational cohort study. We assessed age, dyspnoea, number of comorbidities, history of cancer, neutrophil and lymphocyte counts, neutrophil/lymphocyte ratio, lactate dehydrogenase, and total bilirubin. We also analysed the relationship between mortality and oxygen saturation/fraction of inspired oxygen (SpO 2 /F I O 2 ) and ratio of oxygen concentration to respiratory rate (ROX index). We assessed these data using the Cox proportional hazard and ROC curve models. Results: Survivors (n = 56; mean age 65 years) were younger than those who died (n = 36; mean age 78 years). According to multivariable analysis, multiple comorbidities, history of cancer, CURB-65 score, neutrophil and lymphocyte counts, neutrophil/lymphocyte ratio, and lactate dehydrogenase were all greater in those who died than in those who survived. There were no significant differences in dyspnoea and total bilirubin. The SpO 2 /F I O 2 ratio 3 days after treatment with tocilizumab was strongly associated with subsequent mortality. According to multivariate analysis, of the variables analysed, only the SpO 2 /F I O 2 ratio 3 days after treatment with tocilizumab was significantly associated with mortality rate (p = 0.029; hazard ratio = 0.987, 95% confidence interval 0.977–0.997). Conclusions: The SpO 2 /F I O 2 ratio 3 days after treatment with tocilizumab is a useful prognostic indicator in patients with COVID-19. Our findings indicate that aggressive respiratory therapy and/or additional treatment should be instigated when the SpO 2 /F I O 2 ratio has not improved 3 days after treatment with tocilizumab." @default.
• W4313609299 created "2023-01-07" @default.
• W4313609299 creator A5003513391 @default.
• W4313609299 creator A5007337553 @default.
• W4313609299 creator A5014007006 @default.
• W4313609299 creator A5018928171 @default.
• W4313609299 creator A5021528399 @default.
• W4313609299 creator A5030460953 @default.
• W4313609299 creator A5044050046 @default.
• W4313609299 creator A5044951146 @default.
• W4313609299 creator A5052418789 @default.
• W4313609299 creator A5058198800 @default.
• W4313609299 creator A5072463709 @default.
• W4313609299 creator A5074670360 @default.
• W4313609299 creator A5077511836 @default.
• W4313609299 creator A5079092097 @default.
• W4313609299 creator A5079703667 @default.
• W4313609299 creator A5083455636 @default.
• W4313609299 creator A5083522780 @default.
• W4313609299 creator A5085260283 @default.
• W4313609299 creator A5086729007 @default.
• W4313609299 creator A5087269133 @default.
• W4313609299 date "2023-01-06" @default.
• W4313609299 modified "2023-10-17" @default.
• W4313609299 title "SpO2/FIO2 ratio 3 days after treatment with tocilizumab is a prognostic factor in patients with COVID-19: A retrospective cohort study" @default.
• W4313609299 cites W2089785792 @default.
• W4313609299 cites W2120852203 @default.
• W4313609299 cites W2283987856 @default.
• W4313609299 cites W2906476728 @default.
• W4313609299 cites W3021915688 @default.
• W4313609299 cites W3046629770 @default.
• W4313609299 cites W3085420778 @default.
• W4313609299 cites W3093701219 @default.
• W4313609299 cites W3096942772 @default.
• W4313609299 cites W3110844195 @default.
• W4313609299 cites W3121693389 @default.
• W4313609299 cites W3135288125 @default.
• W4313609299 cites W3155122211 @default.
• W4313609299 cites W3159489301 @default.
• W4313609299 cites W3172804624 @default.
• W4313609299 cites W3181530483 @default.
• W4313609299 cites W3185080609 @default.
• W4313609299 cites W3204205862 @default.
• W4313609299 cites W4206239398 @default.
• W4313609299 cites W4206449744 @default.
• W4313609299 cites W4224252082 @default.
• W4313609299 cites W4224986654 @default.
• W4313609299 doi "https://doi.org/10.21203/rs.3.rs-2441043/v1" @default.
• W4313609299 hasPublicationYear "2023" @default.
• W4313609299 type Work @default.
• W4313609299 citedByCount "0" @default.
• W4313609299 crossrefType "posted-content" @default.
• W4313609299 hasAuthorship W4313609299A5003513391 @default.
• W4313609299 hasAuthorship W4313609299A5007337553 @default.
• W4313609299 hasAuthorship W4313609299A5014007006 @default.
• W4313609299 hasAuthorship W4313609299A5018928171 @default.
• W4313609299 hasAuthorship W4313609299A5021528399 @default.
• W4313609299 hasAuthorship W4313609299A5030460953 @default.
• W4313609299 hasAuthorship W4313609299A5044050046 @default.
• W4313609299 hasAuthorship W4313609299A5044951146 @default.
• W4313609299 hasAuthorship W4313609299A5052418789 @default.
• W4313609299 hasAuthorship W4313609299A5058198800 @default.
• W4313609299 hasAuthorship W4313609299A5072463709 @default.
• W4313609299 hasAuthorship W4313609299A5074670360 @default.
• W4313609299 hasAuthorship W4313609299A5077511836 @default.
• W4313609299 hasAuthorship W4313609299A5079092097 @default.
• W4313609299 hasAuthorship W4313609299A5079703667 @default.
• W4313609299 hasAuthorship W4313609299A5083455636 @default.
• W4313609299 hasAuthorship W4313609299A5083522780 @default.
• W4313609299 hasAuthorship W4313609299A5085260283 @default.
• W4313609299 hasAuthorship W4313609299A5086729007 @default.
• W4313609299 hasAuthorship W4313609299A5087269133 @default.
• W4313609299 hasBestOaLocation W43136092991 @default.
• W4313609299 hasConcept C126322002 @default.
• W4313609299 hasConcept C167135981 @default.
• W4313609299 hasConcept C207103383 @default.
• W4313609299 hasConcept C2777063308 @default.
• W4313609299 hasConcept C2777178219 @default.
• W4313609299 hasConcept C2777513400 @default.
• W4313609299 hasConcept C2777761686 @default.
• W4313609299 hasConcept C2778963024 @default.
• W4313609299 hasConcept C2779134260 @default.
• W4313609299 hasConcept C2780630273 @default.
• W4313609299 hasConcept C29730261 @default.
• W4313609299 hasConcept C44249647 @default.
• W4313609299 hasConcept C50382708 @default.
• W4313609299 hasConcept C71924100 @default.
• W4313609299 hasConcept C74133956 @default.
• W4313609299 hasConcept C90924648 @default.
• W4313609299 hasConceptScore W4313609299C126322002 @default.
• W4313609299 hasConceptScore W4313609299C167135981 @default.
• W4313609299 hasConceptScore W4313609299C207103383 @default.
• W4313609299 hasConceptScore W4313609299C2777063308 @default.
• W4313609299 hasConceptScore W4313609299C2777178219 @default.
• W4313609299 hasConceptScore W4313609299C2777513400 @default.
• W4313609299 hasConceptScore W4313609299C2777761686 @default.
• W4313609299 hasConceptScore W4313609299C2778963024 @default.
• W4313609299 hasConceptScore W4313609299C2779134260 @default.
• W4313609299 hasConceptScore W4313609299C2780630273 @default.
• W4313609299 hasConceptScore W4313609299C29730261 @default.

• next